Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence

被引:9
|
作者
Pereira, Antonio Dias [1 ,2 ]
Chaves, Paula [2 ,3 ]
机构
[1] Inst Portugues Oncol Francisco Gentil, Dept Gastroenterol, Rua Prof Lima Basto, P-1099023 Lisbon, Portugal
[2] Univ Beira Interior, Fac Ciencias Saude, Covilha, Portugal
[3] Inst Portugues Oncol Francisco Gentil, Dept Pathol, Lisbon, Portugal
关键词
Adenocarcinoma; Barrett's esophagus; cancer risk; dysplasia; segment length; surveillance; POPULATION-BASED COHORT; MALIGNANT PROGRESSION; CANCER INCIDENCE; MORTALITY; METAANALYSIS; MANAGEMENT; SURVEILLANCE; ASSOCIATION; GUIDELINES; EXPERIENCE;
D O I
10.1177/2050640615612409
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The risk of esophageal adenocarcinoma (EAC) in non-dysplastic Barrett's esophagus (NDBE) is considered to be approximately 0.3% per year or even lower, according to population-based studies. Data from countries with low EAC incidence are scarce. Our principal aim was to determine the incidence of high-grade dysplasia (HGD) and EAC in NDBE. Our secondary aims were to identify the predictors of progression and to calculate the incidence of HGD/EAC, by using the calculation method for surveillance time in population-based studies. Materials and methods: A cohort of NDBE patients was prospectively followed up. Cases of HGD and EAC (study end points) diagnosed during the first year of follow-up were considered as prevalent. Only cases with an endoscopic surveillance time > 1 year were included in our analysis. Results: We enrolled 331 patients (251 men) in the surveillance program. Their median age was 59 years (interquartile range (IQR): 47-67 years). Their median NDBE length was 3 cm (IQR: 2-4 cm). Of these patients, 80 died during the follow-up (one from EAC) and two were lost to follow-up. After 2284 patient-years of endoscopic follow-up (median surveillance time, 5 years (IQR: 2-10 years)), we found that five cases of HGD and two cases of EAC were diagnosed. The incidence of HGD/EAC was 3.1 cases per 1000 patient-years (95% CI: 1.3-6.0) and that of EAC was 0.9 (95% CI: 0.2-2.9). The incidence of HGD/EAC in short segments (<= 3 cm) was 0.7 cases per 1000 patient-years (95% CI: 0.3-3.4). The sole variable that we found associated with progression was NDBE length. If the total surveillance time was considered (3537 patient-years), the incidence of HGD and EAC was only slight lower. Conclusions: The incidence of HGD and EAC was very low in NDBE. Therefore, current surveillance guidelines must be reassessed, at least for short-segment BE.
引用
收藏
页码:343 / 352
页数:10
相关论文
共 50 条
  • [41] Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter US consortium
    Desai, Madhav
    Lieberman, David A.
    Kennedy, Kevin F.
    Hamade, Nour
    Thota, Prashanthi
    Parasa, Sravanthi
    Gorrepati, Venkat Subhash
    Bansal, Ajay
    Gupta, Neil
    Gaddam, Srinivas
    Young, Patrick E.
    Mathur, Sharad
    Moawad, Fouad J.
    Cash, Brooks D.
    Sampliner, Richard
    Vargo, John J.
    Falk, Gary W.
    Sharma, Prateek
    GASTROINTESTINAL ENDOSCOPY, 2019, 89 (02) : 257 - +
  • [42] Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis
    Yao, Haijuan
    Wang, Le
    Li, Hongyu
    Xu, Shixue
    Bai, Zhaohui
    Wu, Yanyan
    Chen, Hongxin
    Goyal, Hemant
    Qi, Xingshun
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (01) : 79 - 88
  • [43] High-grade dysplasia and intramucosal adenocarcinoma in Barrett's esophagus: the role of endoscopic eradication therapy
    Leggett, Cadman L.
    Prasad, Ganapathy A.
    CURRENT OPINION IN GASTROENTEROLOGY, 2012, 28 (04) : 354 - 361
  • [44] Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett’s Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study
    Vinicius J. Campos
    Guilherme S. Mazzini
    José F. Juchem
    Richard R. Gurski
    Journal of Gastrointestinal Surgery, 2020, 24 : 8 - 18
  • [45] The impact of endoscopic ultrasound findings on clinical decision making in Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma
    Bulsiewicz, W. J.
    Dellon, E. S.
    Rogers, A. J.
    Pasricha, S.
    Madanick, R. D.
    Grimm, I. S.
    Shaheen, N. J.
    DISEASES OF THE ESOPHAGUS, 2014, 27 (05) : 409 - 417
  • [46] Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma
    Buas, Matthew F.
    Gu, Haiwei
    Djukovic, Danijel
    Zhu, Jiangjiang
    Onstad, Lynn
    Reid, Brian J.
    Raftery, Daniel
    Vaughan, Thomas L.
    METABOLOMICS, 2017, 13 (03)
  • [47] Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett’s esophagus, and high-grade dysplasia/esophageal adenocarcinoma
    Matthew F. Buas
    Haiwei Gu
    Danijel Djukovic
    Jiangjiang Zhu
    Lynn Onstad
    Brian J. Reid
    Daniel Raftery
    Thomas L. Vaughan
    Metabolomics, 2017, 13
  • [48] A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia
    Picardo, S. L.
    O'Brien, M. P.
    Feighery, R.
    O'Toole, D.
    Ravi, N.
    O'Farrell, N. J.
    O'Sullivan, J. N.
    Reynolds, J. V.
    DISEASES OF THE ESOPHAGUS, 2015, 28 (02) : 121 - 126
  • [49] Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis
    Yue Chen
    Chenyu Sun
    Yile Wu
    Xin Chen
    Sujatha Kailas
    Zeid Karadsheh
    Guangyuan Li
    Zhichun Guo
    Hongru Yang
    Lei Hu
    Qin Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 2681 - 2691
  • [50] The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: A systematic review and meta-analysis
    Yousef, Fouad
    Cardwell, Chris
    Cantwell, Marie M.
    Galway, Karen
    Johnston, Brian T.
    Murray, Liam
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2008, 168 (03) : 237 - 249